RPRX

Royalty Pharma Plc (RPRX) - Q1 2026 Filing Summary

Business Context and Reporting Period

This Form 10-Q covers the quarterly period ended March 31, 2026. Royalty Pharma Plc is the largest buyer of biopharmaceutical royalties and a leading funder of innovation. The company completed the "Internalization" of its management team on May 16, 2025, transitioning from an externally managed structure to an integrated company. As of March 31, 2026, the company held 443.3 million Class A ordinary shares and 132.6 million Class B ordinary shares outstanding.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Growth: Total income increased 11.0% year-over-year, driven by a 10.3% rise in income from financial royalty assets. Key contributors included the Cystic Fibrosis franchise, Voranigo, and the new Imdelltra royalty acquired in late 2025.
• Expense Increases: General and administrative (G&A) expenses rose 44.1% to $159.5 million, primarily due to $122.3 million in share-based compensation following the Internalization. Interest expense increased 43.6% to $93.7 million due to new debt issuances in 2025 and the assumed Term Loan.
• Impairment Charge: The company recorded a non-cash impairment charge of $69.4 million related to Tazverik following its voluntary withdrawal by Ipsen and Eisai in March 2026.
• Provision Income: The company recognized $197.5 million in provision income (a credit) related to changes in expected cash flows, primarily driven by improved sales forecasts for Evrysdi, Tysabri, and Xtandi.
• Investing Activity: Net cash used in investing activities was $477.9 million, compared to cash provided of $503.9 million in Q1 2025. The shift was due to $452.4 million in acquisitions of financial royalty assets in Q1 2026, whereas Q1 2025 included a $510.6 million sale of MorphoSys bonds.

Guidance, Outlook, and Risks

Management Commentary: Management highlighted strong performance in the Cystic Fibrosis franchise, Trelegy, Evrysdi, and Tremfya. The company continues to deploy capital, investing $527.9 million in royalties and milestones in Q1 2026. The Internalization has eliminated management fees, though it has increased direct employee compensation costs.

Key Developments:

• Acquisitions: Acquired royalties in Denali's Avlayah ($200M) and Zymeworks' Ziihera ($250M). Entered a $500M R&D funding arrangement with Johnson & Johnson for JNJ-4804.
• Product Milestones: Positive Phase 3 results for Revolution Medicines' daraxonrasib triggered a $250M funding tranche in May 2026. Cytokinetics announced positive Phase 3 results for Myqorzo.
• Dividends: Declared a quarterly dividend of $0.235 per Class A share.

Risks and Contingencies:

• Legal Dispute: A dispute with Vertex regarding royalty receipts on Alyftrek net sales began in Q2 2025; resolution is pending.
• Development Risks: Theravance's ampreloxetine failed its Phase 3 primary endpoint, leading to program wind-down.
• Debt Covenants: The company remains in compliance with financial covenants, including a Consolidated Leverage Ratio of 4.00 to 1.00 and a Consolidated Coverage Ratio of 2.50 to 1.00.

Investor Verification Checklist

• Vertex Dispute Status: Verify the current status and potential financial impact of the royalty dispute with Vertex regarding Alyftrek.
• Share-Based Compensation Trajectory: Monitor the run-rate of share-based compensation expenses ($122.3M in Q1) as the Internalization vesting schedules progress.
• Debt Maturity Profile: Review the $380 million Term Loan maturing in July 2026 and the company's refinancing or repayment strategy.
• Development Pipeline Outcomes: Track the regulatory submissions and trial results for funded assets like daraxonrasib, neladalkib, and litifilimab, which drive future royalty streams.
• Portfolio Concentration: Assess the impact of the top five products, which accounted for 62% of Royalty Receipts in Q1 2026.